Latest Operational Efficiency News

Clever Culture Systems has sold its APAS Independence instrument to Novo Nordisk for a comprehensive evaluation across the pharmaceutical giant’s manufacturing network, marking a key step in its global sales strategy.

Beacon Minerals reported solid gold production of 7,365 ounces in the June quarter, maintaining steady operations at its Jaurdi Gold Project while emphasizing a strategy to retain gold bullion as a liquid asset.

Orcoda Limited has locked in six new multi-year SaaS contracts with Australian community transport providers following a successful government-backed trial, pushing its annual recurring revenue to approximately $5 million.

City Chic Collective reports a promising FY25 with a return to profitability driven by strong ANZ sales and disciplined cost management, despite ongoing US market headwinds.

betr Entertainment has achieved positive EBITDA for FY25, exceeding broker forecasts by 15%, driven by successful mergers and technology integration.

Hansen Technologies has raised its FY25 profitability outlook, driven by operational efficiencies and early powercloud profits, despite a slight revenue timing shift. The company also secured major new contracts across Europe and the US.

MyEco Group Ltd reported an 8.6% rise in FY25 sales driven by strong growth in its global MyEco® product line and new UK retail partnerships, while navigating challenges in resin markets and US tariffs.

Top Shelf International Holdings is set to raise up to $10 million through convertible notes to support a strategic business restructure and operational improvements, alongside forging a key sales partnership with Amber Bev.

Pharmx Technologies has extended its pivotal National Diabetes Services Scheme agreement and expanded its supplier base, reinforcing its leadership in pharmacy digital infrastructure across Australia and New Zealand.

GTi Energy has raised $2.5 million from the first tranche of a $4.5 million placement to fund drilling at its Lo Herma uranium project, with key permits expected in August and a strategic investment from Snow Lake Energy pending shareholder approval.

Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.

Spectur Ltd reports a stronger cash position driven by operational improvements and strategic cloud investments, while FY25 revenue slightly misses guidance due to delayed orders.